Balyasny Asset Management LLC Anavex Life Sciences Corp. Transaction History
Balyasny Asset Management LLC
- $61.9 Billion
- Q2 2025
A detailed history of Balyasny Asset Management LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 245,624 shares of AVXL stock, worth $1.97 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
245,624
Previous 171,383
43.32%
Holding current value
$1.97 Million
Previous $1.47 Million
54.01%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding AVXL
# of Institutions
198Shares Held
32MCall Options Held
1.16MPut Options Held
804K-
Black Rock Inc. New York, NY6.39MShares$51.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$41 Million0.0% of portfolio
-
State Street Corp Boston, MA2.95MShares$23.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.02MShares$16.2 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY973KShares$7.82 Million0.02% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $626M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...